TAURUS-MS II:德国特里弗卢诺米德的实际使用以及随着时间的推移治疗模式的变化
Boris-Alexander Kallmann1, Georg Zu Eulenburg2, Jennifer S Kullmann3
1Kallmann Neurologie, Multiple-Sclerosis-Center Bamberg, Bamberg, Germany.
Therapeutic advances in neurological disorders
|May 29, 2024
概括
这项研究表明,teriflunomide显著减少了复发,并改善了复发缓解多发性硬化症 (RRMS) 患者的患者满意度. 现实世界的数据表明,这种口腔疾病修饰疗法的耐受性和有效性很好.
科学领域:
- 神经学 神经学
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 特里弗卢诺米德是一种口服疾病修饰疗法 (DMT),用于复发性复发性多发性硬化症 (RRMS).
- 有限的现实世界数据存在于特里弗卢诺米德的长期有效性和患者报告的结果.
- 在TAURUS-MS II研究的目的是收集全面的真实世界的数据,teriflunomide使用.
研究的目的:
- 收集有关 teriflunomide 在常规临床实践中的使用现实世界的数据.
- 为了比较当前的特里弗卢诺米德使用与先前的TAURUS-MS研究的发现.
- 评估患者满意度和疾病活动随时间变化的变化.
主要方法:
- 进行了一项全国性的,开放的,非干预性的,前性的,多中心的研究.
- 在2017年7月至2022年3月期间,在德国220个医疗机构招募了752名接受特里弗卢诺米德治疗的RRMS患者.
- 收集的数据包括人口统计,多发性硬化病史,先前的治疗,治疗满意度和安全性.
主要成果:
- 在24个月的时间里,teriflunomide治疗导致MS复发的显著减少 (从0.81到0.27).
- 患者报告的结果显示,药物的有效性,方便性和整体满意度有显著改善.
- 副作用通常是可控的,其中氨酸转移酶增加,高血压和脱发是最常见的.
结论:
- 在现实环境中,teriflunomide显著降低了RRMS患者的复发率.
- 与以前的DMT相比,患者对特里弗卢诺米德的满意度显著更高.
- 在临床实践中,特里弗卢诺米德的安全性和耐受性概况与之前的临床试验的发现一致.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Therapy
42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
42
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
124
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
124
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
126
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
126


